首页> 外文OA文献 >Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice
【2h】

Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice

机译:新型细胞因子白介素23(IL-23)和IL-27在HLA-A * 0201转基因小鼠中诱导丙型肝炎病毒特异性细胞毒性T淋巴细胞的佐剂活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Searching the sequence databases has revealed two novel cytokines: interleukin-23 (IL-23) and IL-27. These cytokines are quite similar to, but clearly distinct from IL-12 in their structures and T-cell stimulatory fashions. In contrast to IL-12, however, little is known about the roles of IL-23 and IL-27 in the immune regulation. Previously, we evaluated the prime-boost immunization consisting of priming and the first boosting with the hepatitis C virus (HCV)-core expression plasmid, followed by a second boosting with recombinant adenovirus expressing HCV core for induction of HCV core-specific cytotoxic T lymphocytes (CTLs) in BALB/c mice. The present study demonstrates that HCV-specific CTL induction was greatly enhanced by coinoculation of an IL-12 expression plasmid in the prime-boost immunization, indicating the potent adjuvant activity of IL-12. We investigated whether similar adjuvant effects could be exerted by either IL-23 or IL-27 in a prime-boost immunization with HLA-A*0201 transgenic mice. Coadministration of either an IL-23 or an IL-27 expression plasmid, as well as an IL-12 expression plasmid, in a prime-boost immunization enhanced induction of HCV-specific CTLs and led to dramatic increases in the numbers of gamma interferon (IFN-γ)-producing, HCV-specific CD8+ cells. Further, preinjections of IL-12, IL-23, or IL-27 expression plasmids before immunization resulted in great increases in the number of IFN-γ-producing, HCV-specific CD8+ cells in response to immunization with recombinant adenovirus. These data revealed that both IL-23 and IL-27, as well as IL-12, are potent adjuvants for epitope-specific CTL induction. The two novel cytokines might offer new prophylactic and therapeutic strategies against infectious pathogens such as HCV.
机译:搜索序列数据库发现了两种新型细胞因子:白介素23(IL-23)和IL-27。这些细胞因子在结构和T细胞刺激方式上与IL-12非常相似,但明显不同。然而,与IL-12相反,关于IL-23和IL-27在免疫调节中的作用知之甚少。以前,我们评估了初免-加强免疫,包括初次免疫和首次丙型肝炎病毒(HCV)核心表达质粒加强免疫,然后第二次用表达HCV核心的重组腺病毒进行第二次加强免疫以诱导HCV核心特异性细胞毒性T淋巴细胞(CTL)在BALB / c小鼠中。本研究表明,通过在初免-加强免疫中共接种IL-12表达质粒可大大增强HCV特异性CTL的诱导,表明IL-12具有强大的佐剂活性。我们调查了在用HLA-A * 0201转基因小鼠进行初免-加强免疫中,IL-23或IL-27是否可以发挥类似的佐剂作用。在初免-加强免疫中共同施用IL-23或IL-27表达质粒以及IL-12表达质粒可增强HCV特异性CTL的诱导,并导致γ干扰素数量急剧增加(产生IFN-γ的HCV特异性CD8 +细胞。此外,免疫前对IL-12,IL-23或IL-27表达质粒的预注射导致响应重组腺病毒免疫产生IFN-γ的HCV特异性CD8 +细胞的数量大大增加。这些数据表明,IL-23和IL-27以及IL-12都是表位特异性CTL诱导的有效佐剂。这两种新的细胞因子可能提供针对HCV等传染性病原体的新的预防和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号